BridgeBio Pharma Files 8-K Report
Ticker: BBIO · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1743881
| Field | Detail |
|---|---|
| Company | Bridgebio Pharma, Inc. (BBIO) |
| Form Type | 8-K |
| Filed Date | Jun 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory
TL;DR
BridgeBio Pharma filed a routine 8-K, no major news.
AI Summary
On June 4, 2024, BridgeBio Pharma, Inc. filed an 8-K report detailing an "Other Events" filing. The report does not contain specific financial figures or new material events beyond the filing itself, but it serves as a notification to the SEC.
Why It Matters
This filing indicates BridgeBio Pharma is adhering to its regulatory reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard procedural report and does not disclose any new material risks or significant negative information.
Key Players & Entities
- BridgeBio Pharma, Inc. (company) — Registrant
- June 4, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Palo Alto, CA (location) — Principal Executive Offices
FAQ
What is the purpose of this 8-K filing by BridgeBio Pharma, Inc.?
The 8-K filing is a Current Report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating "Other Events" and "Financial Statements and Exhibits" as of June 4, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on June 4, 2024.
Where are BridgeBio Pharma, Inc.'s principal executive offices located?
BridgeBio Pharma, Inc.'s principal executive offices are located at 3160 Porter Dr., Suite 250, Palo Alto, CA 94304.
What is the company's state of incorporation?
The company's state of incorporation is Delaware.
Does this 8-K filing disclose any specific new material events or financial results?
Based on the provided text, this 8-K filing is categorized under "Other Events" and does not explicitly detail specific new material events or financial results beyond the act of filing itself.
Filing Stats: 470 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-06-06 06:01:23
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share BBIO The Nasdaq Global Se
Filing Documents
- ef20030678_8k.htm (8-K) — 27KB
- ef20030678_ex99-1.htm (EX-99.1) — 23KB
- image2.jpg (GRAPHIC) — 1KB
- image3.jpg (GRAPHIC) — 1KB
- 0001140361-24-029050.txt ( ) — 195KB
- bbio-20240604.xsd (EX-101.SCH) — 4KB
- bbio-20240604_lab.xml (EX-101.LAB) — 21KB
- bbio-20240604_pre.xml (EX-101.PRE) — 16KB
- ef20030678_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On June 4, 2024, BridgeBio Pharma, Inc. issued a press release titled, "BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia." A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release titled, ""BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BridgeBio Pharma, Inc. Date: June 6, 2024 By: /s/ Brian C. Stephenson Brian C. Stephenson, Ph.D., CFA Chief Financial Officer